Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: hCG (human chorionic gonadotropin) Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF

NCT01986374
View directory record Official record
Conditions
Infertility
Interventions
HCG is introduced
Drug
Lead sponsor
Servy Massey Fertility Insititute
Other
Eligibility
21 Years to 47 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 2, 2026, 3:21 PM EDT
Recruiting Phase 1 Interventional

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

NCT04886726
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
uhCG/EGF
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

NCT02427529
View directory record Official record
Conditions
HCG
Interventions
Human Chorionic Gonadotropin, Placebo, Low calorie diet
Drug · Other
Lead sponsor
Dr. Emma's Corporation
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Colts Neck, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF

NCT01687712
View directory record Official record
Conditions
Infertility
Interventions
AFOLIA, Gonal-f® RFF
Drug
Lead sponsor
Fertility Biotech AG
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Tempe, Arizona • Encino, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

NCT01154192
View directory record Official record
Conditions
PCOS
Interventions
Dexamethasone, recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 2, 2026, 3:21 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709
View directory record Official record
Conditions
Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions
GnRH agonist, hCG
Drug
Lead sponsor
UConn Health
Other
Eligibility
21 Years to 33 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

NCT02310919
View directory record Official record
Conditions
Infertility
Interventions
Low dose hCG plus FSH co-trigger, Standard dose of hCG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Not applicable Interventional

IVF Clinical Trial of Two Different Treatment Protocols.

NCT00799929
View directory record Official record
Conditions
Infertility
Interventions
in vitro fertilization (IVF/ICSI)
Other
Lead sponsor
New Hope Fertility Center
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 2, 2026, 3:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion

NCT02179944
View directory record Official record
Conditions
Undesired Pregnancy
Interventions
Not listed
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer

NCT01643993
View directory record Official record
Conditions
Control Media Only, Study hCG and Media
Interventions
hCG at the Time of Embryo Transfer, Control
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 43 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Basking Ridge, New Jersey • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 2, 2026, 3:21 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ITT-5 Mechanisms of Spermatogenesis in Man

NCT02147964
View directory record Official record
Conditions
Gonadotropin Deficiency
Interventions
Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Phase 2 Interventional Results available

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

NCT00505752
View directory record Official record
Conditions
Infertility
Interventions
AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 36 Years · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of hCG on Receptivity of the Human Endometrium

NCT01786252
View directory record Official record
Conditions
Infertility, Subfertility
Interventions
human chorionic gonadotropin (hCG), Placebo Comparator (for hCG)
Drug
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

NCT01004770
View directory record Official record
Conditions
Healthy
Interventions
GE-145 (AN113111) Injection, Visipaque (iodixanol) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Oct 2, 2026, 3:21 PM EDT
Terminated Not applicable Interventional

Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes

NCT04852029
View directory record Official record
Conditions
Infertility, Female
Interventions
Low dose hCG
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 46 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)

NCT02145247
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
hCG
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 2, 2026, 3:21 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Detection of Urinary Human Chorionic Gonadotropin (hCG)

NCT05458778
View directory record Official record
Conditions
Pregnancy Detection
Interventions
Daily test with urine by the product
Device
Lead sponsor
Quanovate Tech Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Ramon, California
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 2, 2026, 3:21 PM EDT
Recruiting Phase 2 Interventional

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

NCT06440850
View directory record Official record
Conditions
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Biospecimen Collection, Cobimetinib, Computed Tomography, Diagnostic Imaging, I-131 Uptake Test, Iodine I-131, Magnetic Resonance Imaging, Positron Emission Tomography, Recombinant Thyrotropin Alfa, Ultrasound Imaging, Vemurafenib
Procedure · Drug · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Can Biotin Supplementation be Used to Mask hCG Abuse?

NCT05450900
View directory record Official record
Conditions
Healthy
Interventions
Choriogonadotropin Alpha, biotin, Microcellulose filler
Drug · Dietary Supplement · Other
Lead sponsor
Sports Medicine Research and Testing Laboratory
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 2, 2026, 3:21 PM EDT
Terminated Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

NCT00042952
View directory record Official record
Conditions
Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage II Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Testicular Seminoma
Interventions
imatinib mesylate, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 2, 2026, 3:21 PM EDT
Not listed No phase listed Observational

Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers

NCT01009723
View directory record Official record
Conditions
Preterm Delivery
Interventions
Not listed
Lead sponsor
Esoterix Genetic Laboratories, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Westborough, Massachusetts • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 2, 2026, 3:21 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

NCT05343572
View directory record Official record
Conditions
Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
Interventions
Plerixafor
Drug
Lead sponsor
Hugh Taylor
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Orange, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 2, 2026, 3:21 PM EDT
Withdrawn Phase 2 Interventional

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00715364
View directory record Official record
Conditions
Stroke
Interventions
NTx™-265: rhCG, then rEPO, Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Oct 2, 2026, 3:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.

NCT00223860
View directory record Official record
Conditions
Hypogonadism, Spinal Cord Injury
Interventions
Human chorionic gonadotropin (hCG), Luteinizing hormone releasing hormone (LHRH)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2008 · Synced Oct 2, 2026, 3:21 PM EDT